News & Events

SANTA CLARA, CA (April 22, 2025) – Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first time, single plasma B-cell discovery services will be part of the company’s exclusive Cellestive antibody discovery platform. The new capability completes a trifecta of B-cell services offered through Cellestive, a platform that already includes discovery pathways for both activated and memory B-cells.  

The new single plasma B-cell service is projected to be of particular value to clients pursuing especially difficult targets in antibody discovery, enabling them both to leverage new processes and technologies and to access broader, deeper data to inform their decision-making.

“This really rounds out our Cellestive platform and allows us to robustly and efficiently interrogate single plasma B-cells for our clients,” said John Kenney, PhD, co-founder and president of Antibody Solutions. “Now, we can capture the entire antigen-specific B-cell repertoire from an immune host by using the hybridoma, memory B-cell, and new plasma B-cell discovery pathways, and get vetted sequences from those pathways. There’s incredible value in being able to combine sequence-based and function-based screening from essentially any cell that’s secreting an antibody. This addition to our Cellestive platform puts Antibody Solutions among a small group of companies with these capabilities.”

The new service will leverage a proprietary technology that has the capacity to interrogate, in a single run, at least ten times more plasma B-cells than current competing technologies. During a run, it can screen antibodies against both soluble antigens and target cells simultaneously, and its AI-driven screening software can rank hits, define multiple unique phenotypes, and prioritize the best clones for recovery. In addition, fast set-up and processing times allow for multiple chips with greater than 1 million capillaries to be run in a single workday, making it ideal for difficult targets that demand maximum throughput with a broad range of parameters. 

“Our clients are under pressure to maximize efficiencies at every step in their discovery process,” Kenney said. “So when we deliver more hits and more screening data – and do it faster and more robustly than with current best-in-class tools – we’re helping our clients get precisely to where they need to be.”

Antibody Solutions’ clients can begin using single plasma B-cell discovery services immediately. Included in each project will be the optimization of analysis conditions, a high-throughput multiparameter screen, recovery of paired heavy and light chain sequences and sequence analysis, high-throughput re-expression, and subsequent analysis including ELISA, Flow Cytometry, and BLI for the validation of antibody binding to the target(s) of interest. 

“We’re confident that our antibody discovery platform can deliver high-quality inputs that will be perfectly tailored to generate the best outputs,” said Kenney. “We reach our goal of exploiting all populations of antigen-stimulated B-cells to discover novel antibody therapeutics. We’re excited to bring Cellestive to a new level and offer truly comprehensive solutions to our clients’ antibody discovery needs.”

Read the official news here.

About Antibody Solutions

Antibody Solutions helps biopharmaceutical companies advance their discovery of better therapeutics and diagnostics by delivering fit-for-purpose antibodies. Using its Cellestive antibody discovery platform, the company provides comprehensive project management and technical support in a fee-for-service, pay-as-you-go business model. Antibody Solutions has served more than 800 clients, including the top 10 global pharmaceutical companies, and can boast a 96% client return rate. Founded in 1995, the company is headquartered in Santa Clara, CA and serves clients worldwide. Learn more at antibody.com.